{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:56:32Z","timestamp":1793372192600,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Dongguan HEC Biopharmaceutical R&D Co., Ltd. and Sunshine Lake Pharma Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40259-025-00715-3","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T15:57:56Z","timestamp":1743782276000},"page":"477-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct05943886","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"1","key":"715_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.dld.2020.08.021","volume":"53","author":"J Kumar","year":"2021","unstructured":"Kumar J, Memon RS, Shahid I, Rizwan T, Zaman M, Menezes RG, et al. Antidiabetic drugs and non-alcoholic fatty liver disease: a systematic review, meta-analysis and evidence map. Dig Liver Dis. 2021;53(1):44\u201351.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"715_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347.","journal-title":"Hepatology"},{"issue":"2","key":"715_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/17460441.2020.1811674","volume":"16","author":"A Do","year":"2021","unstructured":"Do A, Ilagan-Ying YC, Mehal WZ, Lim JK. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opin Drug Discov. 2021;16(2):125\u201334.","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"715_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1751-2980.12830","volume":"21","author":"JT Tang","year":"2020","unstructured":"Tang JT, Mao YM. Development of new drugs for the treatment of nonalcoholic steatohepatitis. J Dig Dis. 2020;21(1):3\u201311.","journal-title":"J Dig Dis"},{"issue":"4","key":"715_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","volume":"7","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol. 2022;7(4):367\u201378.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"10296","key":"715_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink H, Cuthbertson DJ, Wilding J. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296):262\u201376.","journal-title":"Lancet"},{"issue":"12","key":"715_CR7","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324.","journal-title":"N Engl J Med"},{"issue":"12 Suppl. 11","key":"715_CR8","first-page":"6","volume":"20","author":"PN Newsome","year":"2024","unstructured":"Newsome PN, et al. Phase 3 ESSENCE Trial: semaglutide in metabolic dysfunction-associated steatohepatitis. Gastroenterol Hepatol (N Y). 2024;20(12 Suppl. 11):6\u20137.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"715_CR9","doi-asserted-by":"publisher","first-page":"1089214","DOI":"10.3389\/fphar.2022.1089214","volume":"13","author":"Z Chen","year":"2022","unstructured":"Chen Z, Yang L, Liu Y, Huang P, Song H, Zheng P. The potential function and clinical application of FGF21 in metabolic diseases. Front Pharmacol. 2022;13:1089214.","journal-title":"Front Pharmacol"},{"issue":"2","key":"715_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Lawitz EJ, Frias JP, Ortiz-Lasanta G, Johansson L, Franey BB, et al. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study. Lancet Gastroenterol Hepatol. 2023;8(2):120\u201332.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"11","key":"715_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med. 2023;389(11):998\u20131008.","journal-title":"N Engl J Med"},{"issue":"7","key":"715_CR12","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","volume":"29","author":"DL Bhatt","year":"2023","unstructured":"Bhatt DL, Bays HE, Miller M, Cain JE 3rd, Wasilewska K, Andrawis NS, et al. The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nat Med. 2023;29(7):1782\u201392.","journal-title":"Nat Med"},{"key":"715_CR13","doi-asserted-by":"publisher","first-page":"601290","DOI":"10.3389\/fendo.2020.601290","volume":"11","author":"EJ Tillman","year":"2020","unstructured":"Tillman EJ, Rolph T. FGF21: an emerging therapeutic target for non-Alcoholic steatohepatitis and related metabolic diseases. Front Endocrinol (Lausanne). 2020;11:601290.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"715_CR14","doi-asserted-by":"publisher","first-page":"103202","DOI":"10.1016\/j.ebiom.2020.103202","volume":"63","author":"Q Pan","year":"2021","unstructured":"Pan Q, Lin S, Li Y, Liu L, Li X, Gao X, et al. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine. 2021;63:103202.","journal-title":"EBioMedicine"},{"issue":"9","key":"715_CR15","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00228-020-02924-x","volume":"76","author":"A Mishra","year":"2020","unstructured":"Mishra A, Sarangi SC, Reeta K. First-in-human dose: current status review for better future perspectives. Eur J Clin Pharmacol. 2020;76(9):1237\u201343.","journal-title":"Eur J Clin Pharmacol"},{"key":"715_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijms232415627","volume":"23","author":"W Han","year":"2022","unstructured":"Han W, Yang S, Xiao H, Wang M, Ye J, Cao L, et al. Role of adiponectin in cardiovascular diseases related to glucose and lipid metabolism disorders. Int J Mol Sci. 2022;23(24):15627-15646.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"715_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/jmcb\/mjw013","volume":"8","author":"X Hui","year":"2016","unstructured":"Hui X, Feng T, Liu Q, Gao Y, Xu A. The FGF21-adiponectin axis in controlling energy and vascular homeostasis. J Mol Cell Biol. 2016;8(2):110\u20139.","journal-title":"J Mol Cell Biol"},{"issue":"6","key":"715_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3810\/pgm.2014.10.2821","volume":"126","author":"L Kuritzky","year":"2014","unstructured":"Kuritzky L, Umpierrez G, Eko\u00e9 JM, Mancillas-Adame L, Land\u00f3 LF. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med. 2014;126(6):60\u201372.","journal-title":"Postgrad Med"},{"issue":"5","key":"715_CR19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1463-1326.2011.01364.x","volume":"13","author":"P Barrington","year":"2011","unstructured":"Barrington P, Chien JY, Showalter HD, Schneck K, Cui S, Tibaldi F, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(5):426\u201333.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"715_CR20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/dom.14349","volume":"23","author":"S Snitker","year":"2021","unstructured":"Snitker S, Andersen A, Berg B, van Marle S, Sparre T. Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: a randomized, double-blind trial in healthy subjects. Diabetes Obes Metab. 2021;23(6):1415\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"715_CR21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s12325-021-01921-5","volume":"39","author":"J Xu","year":"2022","unstructured":"Xu J, Zhang Y, Li Y, Zhao X, Zhou W, Loghin C, et al. Pharmacokinetics, pharmacodynamics, and safety of dulaglutide after single or multiple doses in Chinese healthy subjects and patients with T2DM: a randomized, placebo-controlled, phase I study. Adv Ther. 2022;39(1):488\u2013503.","journal-title":"Adv Ther"},{"issue":"12","key":"715_CR22","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","volume":"8","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Frias JP, Neff G, Abrams GA, Lucas KJ, Sanchez W, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8(12):1080\u201393.","journal-title":"Lancet Gastroenterol Hepatol."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00715-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00715-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00715-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:26:54Z","timestamp":1745594814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00715-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["715"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00715-3","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"17 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical study was sponsored by Dongguan HEC Biopharmaceutical R&D Co., Ltd. and Sunshine Lake Pharma Co., Ltd..","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lingfeng Guo, Jing Li, Can Xie, and Jiangyu Yan are employees of Dongguan HEC Biopharmaceutical R&D Co., Ltd. and Sunshine Lake Pharma Co., Ltd. Hong Zhang, Qianqian Li, Hong Chen, and Yanhua Ding have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The study protocol was approved by the Ethics Committee of The First Hospital of Jilin University (Changchun, Jilin, China, reference number: 21Y098-002) on 29 April, 2021. The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guideline.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients in this study provided written informed consent to participate.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets supporting the conclusions of this article are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"HZ, QL, HC, JY, and YD contributed to the conception and design of the work, as well as analyses of the data; HZ, QL, and HC managed the clinical trial and performed data acquisition and interpretation; LG, JL, CX, and JY carried out the preclinical studies; HZ wrote the manuscript; HZ, JY, and YD revised the manuscript for intellectual content and collectively approved the final version to be published; and all authors agreed to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}